Replies to post #105468 on Biotech Values

[jq1234]

On a scenario-adjusted basis, we believe M-enoxaparin is worth mid $20’s per share to MNTA.

I would assume "scenario-adjusted basis" uses chance of sole generic. Did Cowen give a concrete number? That might give a little bit idea what "foreseeable future" they are refering to.